Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression.

Amélie AboudaramPierre LoapDelphine LoiratSyrine Ben DhiaKim I CaoAlain FourquetYoulia Kirova

Published in: Cancers (2021)

This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.

Keyphrases

positive breast cancer
epidermal growth factor receptor
early stage
cell proliferation
metastatic breast cancer
transcription factor
radiation induced
binding protein
replacement therapy
smoking cessation